Amgen’s Imdylltra approved in Europe for aggressive solid tumour
Milestone authorisation represents the first T-cell engagement therapy for small cell lung cancer.
The European Commission (EC) has authorised a new first-in-class immunotherapy for extended-stage small cell lung cancer (ES-SCLC).
Amgen’s Imdelltra (tarlatamab) targeted immunotherapy in indicated for adults requiring systemic therapy after disease progression following platinum-based chemotherapy.
As a new treatment option, Imdelltra has been shown to provide a significantly higher survival rate to chemotherapy for these patients. Its approval represents availability of the first T-cell engagement therapy for the rare disease.
The EC’s decision is based on this finding, as seen in the Phase III DeLLphi-304 trial, the first global trial to demonstrate…
Already a member? Sign-in
